COG Cambridge Cognition Holdings Plc

Cambridge Cognition Holdings Plc

("Cambridge Cognition", the "Company" or the "Group")

Director/PDMR Share Purchases

Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, was informed on 13 December 2024 that Stuart Gall, Non-Executive Director of the Company, purchased 31,250 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 32 pence per share.

Following this transaction, Stuart Gall holds an interest in 68,750 Ordinary Shares, representing approximately 0.16% of the Company's issued share capital.

Further information on the purchases is contained in the disclosure tables below.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:

Enquiries:

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a leading technology company specializing in digital health products that advance brain health research and treatment. The Company offers three core products: CANTAB® assessments, which provide scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform, with a large library of instruments, enabling efficient study set up and scalable data capture; and Quality Assurance Tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. Together, these products improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information visit: https://cambridgecognition.com/